- Conditions
- Tourettes Disorder, Tourette Disorder
- Interventions
- ecopipam HCl ~2mg/kg/day
- Drug
- Lead sponsor
- Emalex Biosciences Inc.
- Industry
- Eligibility
- 6 Years to 50 Years
- U.S. locations
- 26
- States / cities
- Glendale, California • San Rafael, California • New Haven, Connecticut + 18 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2545–2568
of 16,860
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Human Immunodeficiency Virus Type 1
- Interventions
- TMC278 25 mg, TMC278 75 mg, TMC278 150 mg, Efavirenz, Non-nucleoside reverse transcriptase inhibitor (NRTIs)
- Drug
- Lead sponsor
- Tibotec Pharmaceuticals, Ireland
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 368 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 9
- States / cities
- Beverly Hills, California • Washington D.C., District of Columbia • Orlando, Florida + 6 more
- Conditions
- Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, HIV Infection, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Non-Hodgkin Lymphoma, Refractory Anemia
- Interventions
- Fludarabine, Cyclophosphamide, Thiotepa, Total-Body Irradiation, Umbilical Cord Blood Transplantation, Dilanubicel
- Drug · Radiation · Procedure + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 6 Months to 65 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 5
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Cleveland, Ohio + 1 more
- Conditions
- Dry Eye Disease (DED)
- Interventions
- 011516X (New Artificial Tear Formulation), Systane Ultra Multidose, REFRESH PLUS®
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 26
- States / cities
- Azusa, California • Glendale, California • Newport Beach, California + 22 more
- Conditions
- Cancer-related Problem/Condition, Neurotoxicity, Pain, Peripheral Neuropathy
- Interventions
- electrical stimulation pain therapy, questionnaire administration
- Other
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Hemoglobinopathy (Disorder), Severe Aplastic Anemia, Bone Marrow Failure Syndrome
- Interventions
- Haploidentical Hematopoietic Cell Transplantation
- Biological
- Lead sponsor
- Johns Hopkins All Children's Hospital
- Other
- Eligibility
- 0 Years to 21 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- St. Petersburg, Florida
- Conditions
- Arsenic Poisoning, Environmental Exposure, Water-Related Diseases
- Interventions
- Water Pitcher Filtration System
- Behavioral
- Lead sponsor
- Trustees of Dartmouth College
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Hematologic Malignancy
- Interventions
- TempTraq, VitalTraq
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Dry Eye, Ocular Inflammation
- Interventions
- Eye wash
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Dry Eye
- Interventions
- Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID, Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID
- Drug
- Lead sponsor
- Aldeyra Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Obesity, Metabolic Syndrome
- Interventions
- olanzapine and melatonin
- Drug
- Lead sponsor
- Seattle Institute for Biomedical and Clinical Research
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2024
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
- Conditions
- Adrenal Hyperplasia, Congenital
- Interventions
- Hydrocortisone sodium acetate
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Myasthenia Gravis, Myopathies, Stroke, Parkinson's Disease
- Interventions
- Not listed
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 20 Years to 90 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Bronchopulmonary Dysplasia (BPD), Respiratory Distress Syndrome, Prematurity; Extreme, Neonatal
- Interventions
- budesonide (Pulmicort nebulizing suspension)., surfactant (poractant alfa;Curosurf)
- Drug
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- Up to 48 Hours
- Enrollment
- 642 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Palo Alto, California • San Diego, California + 15 more
- Conditions
- Mixed Phenotype Acute Leukemia, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Recurrent High Risk Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory High Risk Myelodysplastic Syndrome, Untreated Adult Acute Myeloid Leukemia
- Interventions
- Cladribine, Cytarabine, Decitabine, Filgrastim, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride
- Drug · Biological · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- CARDIOMETABOLIC CONDITIONS, Obesity, Pre-diabetes, Metabolic Syndrome, Type2diabetes, Hypertension, Dyslipidemias
- Interventions
- Base intervention, Augmented Intervention
- Behavioral
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 50 Years to 74 Years
- Enrollment
- 1,029 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • St Louis, Missouri • Pittsburgh, Pennsylvania
- Conditions
- Fatigue Syndrome, Chronic
- Interventions
- Duloxetine, Placebo
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- HIV Infections, Hemophilia A
- Interventions
- Zidovudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1989
- U.S. locations
- 2
- States / cities
- Buffalo, New York • Rochester, New York
- Conditions
- HIV Infections
- Interventions
- MVA/HIV62B vaccine, AIDSVAX B/E vaccine, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 4 more
- Conditions
- Tourette Syndrome
- Interventions
- TEV-50717, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 6 Years to 16 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 19
- States / cities
- Gainesville, Florida • Gulf Breeze, Florida • Miami, Florida + 14 more
- Conditions
- Dry Eye Disease
- Interventions
- OC-01 (varenicline) nasal spray, Placebo (vehicle) nasal spray
- Drug
- Lead sponsor
- Oyster Point Pharma, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 3
- States / cities
- Newport Beach, California • Indianapolis, Indiana • Andover, Massachusetts
- Conditions
- Myofascial Pain, Trigger Point Pain, Myofascial
- Interventions
- Ultrasound, Electrical impedance myography, Excitability testing
- Diagnostic Test
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Transfusional Iron Overload
- Interventions
- ICL670
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 8
- States / cities
- Oakland, California • Orange, California • Boston, Massachusetts + 4 more
- Conditions
- Myasthenia Gravis
- Interventions
- DAS-001
- Drug
- Lead sponsor
- DAS-MG, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas